PMID- 26809939
OWN - NLM
STAT- MEDLINE
DCOM- 20171026
LR  - 20181113
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 12
IP  - 4
DP  - 2016 Apr 2
TI  - Tolerability of 2 doses of pandemic influenza vaccine (Focetria(R)) and of a prior 
      dose of seasonal 2009-2010 influenza vaccination in the Netherlands.
PG  - 1027-32
LID - 10.1080/21645515.2015.1120394 [doi]
AB  - In the Netherlands, people indicated for seasonal influenza vaccination are 
      divided in 3 risk groups, i.e. those less than 60 y (y) with comorbidity and 
      those 60 y and over with and without comorbidity. Those risk groups were also 
      eligible for pandemic vaccination during the 2009 influenza A(H1N1) pandemic. We 
      assessed tolerability of seasonal influenza vaccination and 2 doses of pandemic 
      influenza A(H1N1) vaccine, adjuvanted with MF-59, administered 2 and 5 weeks 
      after seasonal 2009-2010 vaccination among adults. Vaccinees were asked to return 
      questionnaires on local and systemic adverse events (AEs) after each of 3 
      consecutive vaccinations given at the office of their General Practitioner. Sex- 
      and risk group-specific AE-frequencies were calculated. Generalized Linear Mixed 
      Model with seasonal vaccination as reference was used to calculate odds ratios 
      (ORs) for AEs of the 2 pandemic doses. 5553 questionnaires (3251 vaccinees) were 
      returned. Vaccinees reported any local AE after seasonal vaccination and both 
      pandemic doses in 34%, 23%, and 18%, respectively. These percentages were 29%, 
      25%, and 16% for any systemic AE. Men reported fewer local and systemic AEs then 
      women (p<0.0001). The risk of local (OR range 0.34-0.63) and systemic (OR range 
      0.39-0.99) AEs (overall, stratified by risk group and by sex) was lower after 
      both pandemic doses compared to seasonal vaccination. This decreased risk was 
      more pronounced after the second pandemic dose than after the first. Therefore, 
      we conclude that MF59-adjuvanted pandemic vaccine given after seasonal 
      vaccination was well tolerated.
FAU - van der Maas, N A T
AU  - van der Maas NA
AD  - a Centre for Infectious Disease Control, National Institute for Public Health and 
      the Environment (RIVM) , Bilthoven , the Netherlands.
FAU - Godefrooij, S
AU  - Godefrooij S
AD  - a Centre for Infectious Disease Control, National Institute for Public Health and 
      the Environment (RIVM) , Bilthoven , the Netherlands.
AD  - b Department of Health Science, VU University Amsterdam , Amsterdam , the 
      Netherlands.
FAU - Vermeer-de Bondt, P E
AU  - Vermeer-de Bondt PE
AD  - a Centre for Infectious Disease Control, National Institute for Public Health and 
      the Environment (RIVM) , Bilthoven , the Netherlands.
FAU - de Melker, H E
AU  - de Melker HE
AD  - a Centre for Infectious Disease Control, National Institute for Public Health and 
      the Environment (RIVM) , Bilthoven , the Netherlands.
FAU - Kemmeren, J
AU  - Kemmeren J
AD  - a Centre for Infectious Disease Control, National Institute for Public Health and 
      the Environment (RIVM) , Bilthoven , the Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20160125
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Influenza Vaccines)
RN  - 0 (focetria)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Viral/blood
MH  - Female
MH  - Hemagglutination Inhibition Tests
MH  - Humans
MH  - Immunization Schedule
MH  - Influenza A Virus, H1N1 Subtype/immunology
MH  - Influenza Vaccines/administration & dosage/*adverse effects
MH  - Influenza, Human/epidemiology/*prevention & control/virology
MH  - Linear Models
MH  - Male
MH  - Middle Aged
MH  - Netherlands/epidemiology
MH  - Pandemics/*prevention & control
MH  - Seasons
MH  - Surveys and Questionnaires
MH  - Vaccination
MH  - Young Adult
PMC - PMC4962940
OTO - NOTNLM
OT  - adverse event following immunization
OT  - influenza
OT  - pandemic
OT  - seasonal
OT  - tolerability
OT  - vaccination
EDAT- 2016/01/27 06:00
MHDA- 2017/10/27 06:00
PMCR- 2017/01/25
CRDT- 2016/01/27 06:00
PHST- 2016/01/27 06:00 [entrez]
PHST- 2016/01/27 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
PHST- 2017/01/25 00:00 [pmc-release]
AID - 1120394 [pii]
AID - 10.1080/21645515.2015.1120394 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2016 Apr 2;12(4):1027-32. doi: 
      10.1080/21645515.2015.1120394. Epub 2016 Jan 25.